Transforming Growth Factor Beta (Tgf-Beta) Inhibitor – Pipeline Review, 2020

Table of Content:

1. Introduction
   1. Report Overview
2. TGF-Beta Inhibitor  - Overview
3. Executive Summary
4. TGF-Beta Inhibitor  : Pipeline Assessment
   1. By Stage of Development
   2. By Route of Administration
   3. By Drug Class
   4. By Molecule Type
   5. By Therapy Area / Indication
   6. By Drug Target
   7. By Sponsor
5. TGF-Beta Inhibitor : Company & Drug Profiles
   1. Clinical Stage
      1. AVID200 – Forbius (Formation Biologics)
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      2. Galunisertib – Eli Lilly and Company
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      3. TEW-7197 – MedPacto, Inc.
         1. Company Overview
         2. Product Description
         3. R&D Status & Development Activities
         4. Mechanism of Action
         5. Molecule Type
         6. Stage of Development
         7. Indications
         8. Route of Administration
         9. Funding
      4. Others
   2. Preclinical
      1. Company Overview
      2. Product Description
      3. R&D Status & Development Activities
      4. Mechanism of Action
      5. Molecule Type
      6. Indications
      7. Route of Administration
      8. Funding
6. TGF-Beta Inhibitor : An Overview on Dormant & Discontinued Pipeline Candidates
   1. Overview
   2. Product Description
   3. Reason for Discontinuation
7. TGF-Beta Inhibitor : Additional Key Insights
   1. TGF-Beta Inhibitor Applications in Oncology
8. TGF-Beta Inhibitor: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.